Korro Announces $70 Million Private Placement
Korro Bio, Inc. (KRRO)
Company Research
Source: GlobeNewswire
Financing led by Deep Track Capital with participation from other leading healthcare investors Pro-forma cash and cash equivalents of approximately $236 million before fees and expenses On track for regulatory filing for First-in-Human (FIH) study of KRRO-110 in Alpha-1 Antitrypsin Deficiency (AATD) patients anticipated in the second half of 2024Proceeds fund interim readout in the second half of 2025 and FIH study completion in 2026 for KRRO-110 CAMBRIDGE, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today that it has entered into a subscription agreement with certain new and existing accredited investors to issue and sell an aggregate of 1,249,283 shares of its common stock in a private placement (PIPE) that is expected to result in gross proceeds of approximately $70.0 million, before
Show less
Read more
Impact Snapshot
Event Time:
KRRO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KRRO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KRRO alerts
High impacting Korro Bio, Inc. news events
Weekly update
A roundup of the hottest topics
KRRO
News
- Otolith Labs Rounds Out Executive Team with Appointment of Kevin Franck, PhD, MBA as Chief Clinical Officer [Yahoo! Finance]Yahoo! Finance
- Korro to Participate in Upcoming Investor ConferencesGlobeNewswire
- Korro Bio, Inc. (NASDAQ: KRRO) had its price target raised by analysts at HC Wainwright from $100.00 to $115.00. They now have a "buy" rating on the stock.MarketBeat
- Korro Bio, Inc. (NASDAQ: KRRO) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $180.00 price target on the stock.MarketBeat
- Korro Bio, Inc. (NASDAQ: KRRO) had its price target raised by analysts at Royal Bank of Canada from $70.00 to $90.00. They now have an "outperform" rating on the stock.MarketBeat
KRRO
Sec Filings
- 5/1/24 - Form DEFA14A
- 4/29/24 - Form ARS
- 4/29/24 - Form DEFA14A
- KRRO's page on the SEC website